文献速递血管炎

抗白介素-5/受体治疗嗜酸性肉芽肿性多血管炎的两年疗效与安全性

Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis.
PubMed 文献 · Ann Rheum Dis · 2025-08-07

MANDARA试验开放标签扩展期纳入128例EGPA患者,比较继续本瑞利珠单抗(本瑞利珠单抗/本瑞利珠单抗)与由美泊利珠单抗转换至本瑞利珠单抗(美泊利珠单抗/本瑞利珠单抗)至第104周的疗效与安全性。第104周两组缓解率分别为62.1%与67.7%,开放标签扩展期第1年无复发率分别为77.3%与67.7%;转换后血嗜酸性粒细胞计数从70个/µL降至20个/µL,并减少口服糖皮质激素用量。

要点

  • 第104周本瑞利珠单抗/本瑞利珠单抗组缓解41例(62.1%),美泊利珠单抗/本瑞利珠单抗组42例(67.7%)。
  • 开放标签扩展期第1年无复发:本瑞利珠单抗/本瑞利珠单抗组51例(77.3%),美泊利珠单抗/本瑞利珠单抗组42例(67.7%)。
  • 美泊利珠单抗/本瑞利珠单抗组转换后4周血嗜酸性粒细胞计数由70个/µL降至20个/µL。

核心结论

  • 在EGPA患者中,接受抗IL-5/R治疗2年与持久的缓解率、口服糖皮质激素停用、血嗜酸性粒细胞清除及低复发率相关。
  • 由美泊利珠单抗转换至本瑞利珠单抗可增强血嗜酸性粒细胞清除并减少口服糖皮质激素用量。

研究设计与样本

  • MANDARA试验52周双盲期内患者按1:1随机接受本瑞利珠单抗或美泊利珠单抗每4周一次,随后进入开放标签扩展期,继续本瑞利珠单抗(本瑞利珠单抗/本瑞利珠单抗)或由美泊利珠单抗转换至本瑞利珠单抗(美泊利珠单抗/本瑞利珠单抗)。
  • 共128例患者进入开放标签扩展期(本瑞利珠单抗/本瑞利珠单抗组66例;美泊利珠单抗/本瑞利珠单抗组62例)。

主要发现

  • 第104周本瑞利珠单抗/本瑞利珠单抗组41例(62.1%)和美泊利珠单抗/本瑞利珠单抗组42例(67.7%)处于缓解(伯明翰血管炎活动评分=0且口服糖皮质激素剂量≤4 mg/d)。
  • 开放标签扩展期第1年,本瑞利珠单抗/本瑞利珠单抗组51例(77.3%)和美泊利珠单抗/本瑞利珠单抗组42例(67.7%)无复发。
  • 第49至52周,本瑞利珠单抗/本瑞利珠单抗组27例(40.9%)和美泊利珠单抗/本瑞利珠单抗组16例(25.8%)已停用口服糖皮质激素,至第101至104周分别增至29例(43.9%)和27例(43.5%)。
  • 开放标签扩展期第1年中位累积口服糖皮质激素剂量分别为950 mg和791 mg。
  • 本瑞利珠单抗/本瑞利珠单抗组中位血嗜酸性粒细胞计数为20个/µL(第52周和第100周);美泊利珠单抗/本瑞利珠单抗组转换后4周由70个/µL降至20个/µL。

关键数值与推荐

  • 缓解定义:伯明翰血管炎活动评分=0且口服糖皮质激素剂量≤4 mg/d。
  • 第104周缓解率:本瑞利珠单抗/本瑞利珠单抗组62.1%,美泊利珠单抗/本瑞利珠单抗组67.7%。
  • 开放标签扩展期第1年无复发率:本瑞利珠单抗/本瑞利珠单抗组77.3%,美泊利珠单抗/本瑞利珠单抗组67.7%。
  • 第49至52周停用口服糖皮质激素比例:本瑞利珠单抗/本瑞利珠单抗组40.9%,美泊利珠单抗/本瑞利珠单抗组25.8%。
  • 第101至104周停用口服糖皮质激素比例:本瑞利珠单抗/本瑞利珠单抗组43.9%,美泊利珠单抗/本瑞利珠单抗组43.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To summarise the efficacy and safety of 2 years of anti-interleukin-5/receptor (anti-IL-5/R) therapy in patients with eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Patients were randomised 1:1 to receive benralizumab or mepolizumab every 4 weeks during the 52-week double-blind period of the MANDARA trial. Patients entered an open-label extension (OLE) in which they continued benralizumab (benralizumab/benralizumab) or switched from mepolizumab to benralizumab (mepolizumab/benralizumab). Remission (Birmingham Vasculitis Activity Score = 0 and oral glucocorticoid [OGC] dose ≤4 mg/d), OGC use, relapse, blood eosinophil count (bEOS), and safety up to year 2 (week 104) were reported. RESULTS: A total of 128 patients entered the OLE period (n = 66 benralizumab/benralizumab; n = 62 mepolizumab/benralizumab). At week 104, 41 (62.1%) benralizumab/benralizumab patients and 42 (67.7%) mepolizumab/benralizumab patients were in remission. During OLE year 1, 51 (77.3%) benralizumab/benralizumab patients and 42 (67.7%) mepolizumab/benralizumab patients had no relapses. By weeks 49 to 52, 27 (40.9%) benralizumab/benralizumab patients and 16 (25.8%) mepolizumab/benralizumab patients had withdrawn from OGCs, increasing to 29 (43.9%) and 27 (43.5%) at weeks 101 to 104, respectively; the median cumulative OGC dose was 950 mg and 791 mg during OLE year 1, respectively. The median bEOS among benralizumab/benralizumab-treated patients was 20 cells/µL (at weeks 52 and 100), and in mepolizumab/benralizumab-treated patients, it decreased from 70 cells/µL to 20 cells/µL 4 weeks after switching. Adverse events/serious adverse events were reported in 97.0%/22.7% of benralizumab/benralizumab and 100%/35.5% of mepolizumab/benralizumab patients. CONCLUSIONS: In patients with EGPA, treatment for 2 years with anti-IL-5/R therapies is associated with durable rates of remission, discontinuation of OGCs, bEOS depletion, and low relapse rates. Switching from mepolizumab to benralizumab enhances bEOS depletion and OGC sparing.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Merkel PA, Nair PK, Khalidi N, et al. Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2025. PMID: 40781045. doi:10.1016/j.ard.2025.06.2131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。